TY - JOUR
T1 - The benefits of early intervention using lenalidomide for high-risk smoldering multiple myeloma
T2 - emerging data and its promising clinical impact
AU - Kunacheewa, Chutima
AU - Manasanch, Elisabet E.
N1 - Publisher Copyright:
© 2021 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2021
Y1 - 2021
N2 - Introduction: Multiple myeloma is preceded by the early stages: monoclonal gammopathy of unknown significance (M.G.U.S.) and smoldering myeloma (S.M.M.), which are less genomically complex and where patients are overall healthier with preserved quality of life. Areas covered: This review focuses on the current evidence in risk stratification and initial therapy for these patients with the goal to delay progression to and/or cure multiple myeloma. Expert opinion: Advances in the understanding of the factors that contribute to myeloma evolution coupled with new therapeutics that have high efficacy and limited toxicity have revolutionized our approach to early myeloma. Although our current recommendation continues to be to observe S.M.M. outside of clinical trials, the clinical benefit of lenalidomide sets the stage for combinations with immunotherapy, which, in our opinion, will likely lead to regulatory approvals and more widespread treatment of early myeloma.
AB - Introduction: Multiple myeloma is preceded by the early stages: monoclonal gammopathy of unknown significance (M.G.U.S.) and smoldering myeloma (S.M.M.), which are less genomically complex and where patients are overall healthier with preserved quality of life. Areas covered: This review focuses on the current evidence in risk stratification and initial therapy for these patients with the goal to delay progression to and/or cure multiple myeloma. Expert opinion: Advances in the understanding of the factors that contribute to myeloma evolution coupled with new therapeutics that have high efficacy and limited toxicity have revolutionized our approach to early myeloma. Although our current recommendation continues to be to observe S.M.M. outside of clinical trials, the clinical benefit of lenalidomide sets the stage for combinations with immunotherapy, which, in our opinion, will likely lead to regulatory approvals and more widespread treatment of early myeloma.
KW - Smoldering multiple myeloma
KW - high-risk smoldering multiple myeloma
KW - immunotherapy
KW - lenalidomide-based regimen
UR - http://www.scopus.com/inward/record.url?scp=85116057980&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85116057980&partnerID=8YFLogxK
U2 - 10.1080/17474086.2021.1984225
DO - 10.1080/17474086.2021.1984225
M3 - Review article
C2 - 34550841
AN - SCOPUS:85116057980
SN - 1747-4086
VL - 14
SP - 1059
EP - 1069
JO - Expert review of hematology
JF - Expert review of hematology
IS - 12
ER -